Navigation Links
New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis
Date:11/10/2010

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis -- STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

New Study Published: Lactobacillus reuteri Prodentis Effective in the Treatment of Periodontitis

 
Download image

STOCKHOLM, November 10, 2010 /PRNewswire-FirstCall/ -- The study shows that L. reuteri Prodentis acts synergistically with standard treatment (scaling and root plaining, SRP) to significantly reduce probing pocket depth (PPD) and clinical attachment level (CAL) which are the two most important parameters to assess the severity of periodontitis. Furthermore L. reuteri Prodentis reveals - as the first probiotic ever - significant reductions of three different pathogens in patients with chronic periodontitis. The study also confirms the anti-inflammatory effects of L. reuteri Prodentis on gum inflammation (gingivitis).

(Photo: http://www.newscom.com/cgi-bin/prnh/20101110/418565 )

Chronic periodontitis occurs in up to 40 % of the adult population. The standard treatment aims at removing plaque in the dental pockets to reduce the periodontal pathogens and thereby prevent disease progression.

Thirty chronic periodontitis patients were included in the double blind, randomized, placebo-controlled clinical trial that lasted for 42 days. On day 0 the teeth in one half of the mouth were treated with SRP whereas the teeth in the other half were left untreated. From day 21 to day 42 the patients were supplemented with either L. reuteri Prodentis lozenges (1X108 CFU DSM 17938 and 1x108 CFU ATCC PTA 5289) or placebo lozenges twice daily.

The result showed that a combination of L. reuteri Prodentis and SRP was significantly better than all other modalities in reducing gingivitis and plaque. Moreover, L. reuteri Prodentis, either alone or following SRP, significantly reduced the pathogens Aggregibacter actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia by up to 90 % as compared to the treatments that did not include L. reuteri Prodentis. The combination of L. reuteri Prodentis and SRP was also significantly better than SPR alone in reducing both PPD (p<0.001) and CAL (p<0.001), see attachment.

- This short-term study proves that L. reuteri Prodentis by itself has a powerful effect on the pathogens of periodontitis and that the combination of L. reuteri Prodentis and SRP synergistically improves both PPD and CAL, says Professor Vandana at the College of Dental Science in Davangere, India. - The results strengthen L. reuteri Prodentis position as a proven treatment option for patients with periodontal disease, says Peter Rothschild, President, BioGaia AB.

The results of the study were published online on the 2nd of November 2010 in the Journal of Oral Microbiology, doi: 10.3402/jom.v2i0.5344. The study can be accessed at: http://www.journaloforalmicrobiology.net/index.php/jom/article/view/5344

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. http://www.biogaia.com


'/>"/>
SOURCE BioGaia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years
4. New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
5. Sermo Study Shows 63% of Physicians Would Utilize New Gout Treatments
6. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
9. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
10. Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study
11. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... Global  urinalysis market  is ... 2022, according to a new report by Grand ... http://photos.prnewswire.com/prnh/20150105/723757 ) , Automation is ... accuracy delivered by the new generation urinalysis devices ... instruments and consumables. For instance, the automatic bench-top ...
(Date:4/26/2016)... Holdings, Inc. (NYSE: HRC ) invites you to ... st Annual Health Care Conference on Wednesday, May 4, ... to listen to the live discussion via the internet link ... http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the discussion will be ... accessible at the links above until August 1, 2016. ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... Amada Senior Care, premier provider of non-medical in-home care and ... San Antonio West location. Prior to entering the senior care industry, Amada franchise partner ... Amada San Antonio West will take place on Friday, April 29th. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Point Source ... microphones and headsets announced today that the US Patent Office has approved its ... a structure. This innovative design creates a lightweight and modular audio headset that ...
(Date:4/28/2016)... Tamarac, FL (PRWEB) , ... April 28, 2016 , ... ... body recovery supplement GlycoLoad at this week’s 2016 Europa Games Get Fit and ... health conscious consumers alike, the Europa Orlando Expo coming up April 29-30, was selected ...
(Date:4/28/2016)... Washington, D.C. (PRWEB) , ... April 28, 2016 , ... ... Control and Prevention (CDC) has established an ICD-10-CM code for sarcopenia, giving it recognition ... by the medical community effective October 1, 2016. , Sarcopenia is defined as a ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... health insurance co-operative bankruptcy to receive their prescription medications through America’s fastest-growing ... FDA-approved prescription medications from over 180 American pharmaceutical companies for $35 per ...
Breaking Medicine News(10 mins):